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Abstract: Autophagy is an evolutionary conserved catabolic process that allows for the degradation
of intracellular components by lysosomes. This process can be triggered by nutrient deprivation,
microbial infections or other challenges to promote cell survival under these stressed conditions.
However, basal levels of autophagy are also crucial for the maintenance of proper cellular homeostasis
by ensuring the selective removal of protein aggregates and dysfunctional organelles. A tight
regulation of this process is essential for cellular survival and organismal health. Indeed, deregulation
of autophagy is associated with a broad range of pathologies such as neuronal degeneration,
inflammatory diseases, and cancer progression. Ubiquitination and deubiquitination of autophagy
substrates, as well as components of the autophagic machinery, are critical regulatory mechanisms of
autophagy. Here, we review the main evidence implicating deubiquitinating enzymes (DUBs) in the
regulation of autophagy. We also discuss how they may constitute new therapeutic opportunities in
the treatment of pathologies such as cancers, neurodegenerative diseases or infections.
Keywords: autophagy; DUB; deubiquitinating enzymes; inhibitor; aggrephagy; mitophagy;
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1. Introduction
Autophagy is a lysosomal catabolic process that ensures the degradation and recycling of
intra-cytoplasmic components and, therefore, highly contributes to the maintenance of cellular
homeostasis. In order to adapt to various stresses and promote its survival under challenging
conditions, the cell also uses autophagy to degrade a broad range of endogenous or exogenous
substrates [1]. The best-studied endogenous substrates of autophagy are mitochondria and protein
aggregates [2–4]. Defects in the elimination of such substrates are often associated with human
pathologies, including neurodegenerative diseases or cancers [5–7].
Autophagy is a very dynamic process and has to be tightly regulated to provide a timed and
efficient response to a multitude of signals. Posttranslational modifications play a significant role in the
induction and regulation of autophagy [8,9]. Ubiquitination of substrates and protein of the autophagy
machinery has notably emerged as a central regulatory mechanism of autophagy acting at various
levels to promote autophagy induction or shutdown [10,11].
Ubiquitination is a reversible protein modification that consists of the covalent attachment of
one or several ubiquitin moieties to protein substrates [12–14]. While ubiquitination is achieved by
the sequential action of E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and an E3
ubiquitin ligase, the removal of ubiquitin from a protein is catalyzed by deubiquitinating enzymes
(DUBs) [15]. Ubiquitination can promote or interfere with protein-protein interactions, modifying the
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conformation or the activity of the targeted protein or direct proteins for degradation by either the
proteasome or the autophagy process [16,17]. Ubiquitin linkage is involved in most, if not all, cellular
processes and signaling pathways. As for autophagy, defects in ubiquitination and deregulation of
DUBs are associated with human disorders [18–20].
Here, we chose to focus on the role of DUBs related to the regulation of autophagy and cargo
lysosomal degradation. We extended our review to the recent development of small-molecule inhibitors
modulating DUBs’ activity on autophagy, thus highlighting their potential as therapeutic targets.
2. Autophagy and Ubiquitin System: A Brief Overview
2.1. Autophagy
Autophagy was first described in 1966 by C. de Duve and R. Wattiaux based on observations from
mammalian cells deprived of serum and amino acids [21]. The name autophagy was coined later, after
electron microscopy observations that revealed the presence of double-membrane vesicles containing
part of the cytoplasm. Autophagy can be induced in response to various stressors such as lack of
nutrients or growth factors, hypoxia, or infection [22]. As such, autophagy was initially described
as a survival mechanism in response to various stresses. However, it is now widely recognized that
basal levels of autophagy also operate independently of any stress, contributing to the maintenance
of cellular homeostasis by the removal of dysfunctional or unnecessary proteins and organelles (for
instance, mitochondria) and ribosomes [2].
One can distinguish three types of autophagy: macroautophagy (mostly referred to as autophagy),
chaperone-mediated autophagy and microautophagy. These autophagy processes differ by the way
substrates are being delivered to the lysosome for degradation. In macroautophagy, autophagy
substrates are isolated from the cytoplasm through their engulfment in double-membrane vesicles
called autophagosomes [23]. Autophagosomes are formed by the elongation of an isolation membrane
derived from the endoplasmic reticulum [24]. The autophagosomes eventually mature and fuse
with the lysosomes where hydrolases degrade the substrates (Figure 1). In chaperone-mediated
autophagy, soluble cytosolic proteins are recruited by the chaperone HSC70/HSP8A and directly
translocated into the lysosome through pores made of LAMP2A multimers. Substrate translocation
into the lysosome requires a second HSC70 chaperone resident in the lysosomal lumen [25–27].
In microautophagy, cytosolic substrates are transferred to the lysosome through direct invagination
of the lysosomal membrane (in yeast) or from the late endosomes (in mammals and Drosophila,
referred to as endosomal-microautophagy) that eventually fuse with the lysosomes [28–30]. As for
chaperone-mediated autophagy, endosomal-microautophagy requires the chaperone protein HSC70
for the selection of the substrates [28,30,31].
The major components of the autophagy machinery are the ATG (autophagy-related gene)
proteins, which are required for the formation and maturation of the autophagosome (Figure 1).
ATG proteins form specific macromolecular complexes acting at several steps of autophagosome
formation and regulating different stages of the autophagy process [23]. Autophagy induction by
starvation is controlled by the TOR (target of rapamycin) complex 1, which is an essential signaling
pathway for the sensing of nutrient availability [32]. Lack of nutrients leads to the down-regulation
of TOR activity, resulting in the activation of the ULK1/ATG1 complex. The activation of the ULK1
complex then initiates autophagy by recruiting other ATG proteins to the nascent autophagosome.
Downstream ULK1 complex, the class III PtdIns3K (PI3K-III) complex, is responsible for the production
of phosphatidylinositol-3-phosphate (PtdIns3P), which triggers the proper localization and membrane
association of other ATG proteins [33]. Beclin1, a multivalent adaptor, is one major component of
the PI3K-III complex. The expansion of the autophagosomal membrane requires two ubiquitin-like
conjugation cascades: the Atg12-conjugation system and the Atg8/LC3-conjugation system. The
modification of the Atg8 protein by lipidation and its anchorage in the autophagosome membrane
is a hallmark of autophagy induction [34–36]. After completion and closure, the autophagosome is
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targeted to and fuses with the lysosome, leading to the degradation of its content. Posttranslational
modifications on autophagy regulators contribute to the rapid and efficient response to various stresses.
If attention is focused first on phosphorylation, a growing body of evidence shows that ubiquitination
also plays a crucial role in the dynamic regulation of autophagy notably by targeting substrates to
autophagosome, and modifying the activity of ULK1 and PI3K-III complexes [11,37,38].
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Figure 1. An overview of the macroautophagy process. Initiation of autophagy is under the control of
sensor pathways that can sense the availability of nutrients, growth factors, insulin or other stresses.
The main regulators of autophagy are AMPK (AMP-activated kinase) and mTORC1 (mTOR complex
(1) which act as autophagy activator and inhibitor, respectively. AMPK and mTORC1 regulate the
activation of the ULK1 complex which, together with the PI3K-III complex, initiates the autophagosome
formation. The formation of an autophagosome starts with the generation of a phagophore which
elongates into an isolation membrane where the cargos to be degraded are gathered. The enclosure
of the isolation membrane forms a double-membraned autophagosome that matures and eventually
fuses with the lysosome, forming an autolysosome where lysosomal hydrolases degrade its content.
The Atg12 and LC3 conjugation systems are essential for the autophagy process and formation of the
autophagosome. The Atg12 conjugation system consists in the formation of the Atg12-Atg5-Atg16L1
complex that then promotes the conjugation of LC3; pro-LC3 is cleaved by Atg4 (LC3-I) which is
then conjugated with phosphatidylethanolamine (PE) (LC3-II) before being anchored to the nascent
autophagosomal membrane.
2.2. Ubiquitin System
Ubiquitin is a small globular protein with a β-grasp superfold conformation [39,40]. Ubiquitin
is covalently conjugated by its terminal glycine (G76) onto a lysine residue of a substrate protein.
Protein ubiquitination is a complex process requiring the successive activity of three types of enzymes:
an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligase
enzyme. The ubiquitination process can be broken down in two main steps: (1) The ATP-dependent
activation of a ubiquitin molecule by conformational modification of its C-terminus extremity by
an E1 enzyme followed by its transfer onto an E2 enzyme, and (2) the conjugation of the activated
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ubiquitin onto a substrate protein, mediated by an E3 enzyme that bridges the E2 to a specific substrate
allowing for the subsequent transfer of ubiquitin from the E2 enzyme to the substrate through the
formation of an isopeptide bond [41,42]. Alternatively, E3 ligases of the HECT family possess E2 and
E3 activities [43,44]. There is also evidence for the addition of ubiquitin moieties onto non-lysine
residues. The ubiquitination of cysteine or serine and threonine residues requires the formation of
thiol- or oxy-ester bonds respectively [45].
Ubiquitination was discovered in 1980 and first described for its essential role in targeting proteins
to the proteasome for degradation [46]. It is now widely recognized that ubiquitination also acts in other
cellular processes. Indeed, a broad range of types of ubiquitination have been reported. Substrates
can be modified by the attachment of a single ubiquitin molecule (mono-ubiquitination) or several
single ubiquitin molecules on different lysine residues of the substrate (multi-mono-ubiquitination).
Mono-ubiquitination is primarily described for its function in endocytosis of plasma membrane
receptors [47]. Alternatively, several ubiquitin molecules can be ligated to one another using ubiquitin
internal lysine residues, forming chains of ubiquitin moieties that can elongate on the substrate or
directly be attached to a target protein (poly-ubiquitination). Because ubiquitin has seven lysine
residues, there can be at least as many types of ubiquitin chains that can be generated (K6, K11, K29,
K48, K63-linked ubiquitin chains) [48,49]. Poly-ubiquitin chains can also be assembled through N- to
C-terminal interaction to form linear chains (M1) [50,51]. The tridimensional structures of ubiquitin
chains vary depending on the lysine in the ubiquitin used to generate the chain and affect the function
or stability of the substrate. For instance, K48-linked ubiquitin chains have a compact conformation
and target substrates for proteasomal degradation, while K63-linked ubiquitin chains display an open
conformation and are mostly described to promote signal transduction through the assembly of large
protein complexes [52,53].
Protein ubiquitination is a reversible posttranslational modification. The hydrolysis of ubiquitin
linkages is conducted by a specific family of proteases: the DUBs. These enzymes can act at different
stages of the protein ubiquitination process: (1) At the “initial” stage, by cleaving the ubiquitin
precursors to supply ubiquitin monomers to the ubiquitination enzymes; (2) at the “intermediate”
stage, by the regulated removal of ubiquitin moieties from proteins to alter their fate (stabilization,
conformational change); and (3) at the “final” stage by the removal of ubiquitin chains from substrates
addressed to the proteasome to facilitate their degradation and processing into ubiquitin monomers,
free to enter a new ubiquitination cycle (Figure 2) [54–56]. The hydrolysis of K48-linked ubiquitin
chains, most well-known to induce the proteasomal degradation, can affect the fate of the protein
they are added to either by protecting substrates from degradation or by supporting proteasomal
degradation, as the removal of K48-linked ubiquitin chains, mostly by proteasomal DUBs, is also
required for protein entry into the proteasome [57,58].
There are approximately 100 DUBs encoded by the human genome [15,59], which are divided
into two main families: the cysteine proteases and the metalloproteases. There are 12 DUBs
from the metalloprotease family characterized by a JAMM (JAB1/PAB1/MPN domain-containing
metalloenzymes) domain that catalyzes the hydrolysis of isopeptide bonds in the presence of Zn2+.
Cysteine proteases are divided into five sub-families according to the sequence and structure of
their catalytic domain: ubiquitin-specific proteases (USPs), ubiquitin C-hydrolases (UCHs), otubain
proteases (OTUs), Machado Joseph disease proteases (MJDs), and the most recently identified
sub-family MIU-containing novel DUB family (MINDYs). The most abundant sub-family of DUBs is
the USPs with over 50 members, come after the OTUs (18 members), UCH, MJDs and MINDYs (each
with four members) [15].
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Figure 2. Localization of the action of DUBs in the ubiquitination process. Ubiquitination is catalyzed
by three types of enzymes: E1, E2, E3. It is a reversible reaction. DUBs process ubiquitin chains at three
level: (A) For the generation of ubiquitin monomers from a ubiquitin precursor; (B) for the selective
removal of ubiquitin moieties on ubiquitinated proteins; and (C) for the recycling of ubiquitin from
protein degraded by the proteasome.
3. Deubiquitinating Enzymes Involved in Autophagy
Protein posttranslational modifications are crucial in the dynamic regulation of the autophagy
process. Modifications of core components of the autophagic machinery are notably essential for the
induction of autophagy. Autophagy proteins that are ubiquitinated constitute substrates for DUBs,
therefore regulating their function and/or stability [60].
3.1. Regulation of Early Steps of Autophagy
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t . The protease OTUB1 was recently reported to inhibit mTORC1 activity by deubiquitinating
and stabilizing the inhi itor DEPTOR in response to amino acid deprivation [61] (Figure 3A).
DEPTOR stabilization by OTUB1 depends on its catalytic activity as the c talytically inactive mutant
OTUB1-C91A fails to both remove ubiquitin moieties from DEPTOR and protect it from proteasomal
degradation. Consistent with these observations, OTUB1 overexpression induces autophagy while its
knockdown represses autophagy induction [61].
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3.1.2. Regulation of ULK1 by USP20
The serine/threonine protein kinase ULK1 (Unc51-like kinase 1) is a critical inducer of
autophagy (see above and Figure 1). Dynamic phosphorylation and polyubiquitination regulate
ULK1 activity. Notably, the ubiquitination of ULK1 with K63-linked ubiquitin chains contributes
to its stabilization and activity [38]. In contrast, the linkage of K48-linked ubiquitin chains leads to
proteasomal degradation of ULK1, resulting in a blockade of starvation-induced autophagy [62,63].
A loss-of-function screen of DUBs in HeLa cells identified USP20 as the first DUB to be involved in
regulating ULK1 ubiquitination and stability. USP20 interacts with and deubiquitinates ULK1, thus
protecting it from degradation. The maintenance of basal levels of ULK1 by USP20 contributes to rapid
induction of autophagy under stress condition. Indeed, silencing of USP20 encoding gene inhibits
autophagosomes and autolysosomes formation in response to starvation (Figure 3B). However, the
interaction between ULK1 and USP20 is weakened upon prolonged induction of autophagy (4 to 8 h),
leading to a reduction of the level of ULK1 protein while its ubiquitinated form accumulates [64]. The
molecular mechanisms regulating the dissociation of USP20 and ULK1 are not known yet but could
depend on posttranslational or allosteric modifications on USP20 as its stability is not affected by
starvation; alternatively, the E3 ubiquitin ligase NEDD4L, may compete with USP20 to interact with
ULK1 and promotes its proteasomal degradation [63].
3.1.3. Regulation of the Beclin1 Complex
Beclin1 is a multivalent adaptor protein and forms, with VPS34 and VPS15, the core components of
the PI3K-III signaling complex, which is essential for the maturation of the autophagosome (see above
and Figure 1). Beclin1 also interacts transiently with accessory factors, such as ATG14L, AMBRA1,
UVRAG or Bcl-2 [65]. Moreover, Beclin1 versatile ubiquitination is tightly linked to its function and
activation [37]. Different types of ubiquitin chains, including K63- and K48-linked chains, were found
on Beclin1, and several DUBs control Beclin1 ubiquitination status and activity (Figure 3C).
USP14 is a ubiquitin-specific protease tightly associated with the proteasome which has been
shown to cleave K48-linked ubiquitin chains [66,67]; however, other studies have shown that USP14 is
also able to cleave K63-linked ubiquitin chains [68,69]. Knockdown of USP14 or its inhibition with
the inhibitor IU1 (see below Section 4.1) induces the activation of autophagy, indicating that USP14 is
a negative regulator of autophagy in H4 (neuroglioma) cells. Because silencing the USP14 encoding
gene does not affect the stability of Beclin1 or other components of the complex, this suggests that its
ability to regulate autophagy is independent of its proteasomal function in H4 (neuroglioma) cells.
According to this observation, it was shown that USP14 suppresses the activity of Beclin1 complex
and induction of autophagy by interacting with and controlling K63- rather than K48-linked ubiquitin
chains of Beclin1 [70].
Autophagy is highly interconnected with immune processes and can be triggered by activated
TLR4 (Toll-like receptor 4). Activation of TLR4 by microbial components contributes to the recruitment
of adaptor proteins and enzymes required for the signal transduction and induction of the immune
response by NF-κB (nuclear factor kappa B) transcription factors, such as the E3 ubiquitin ligase
and scaffold protein TRAF6 (TNFR-associated factor 6). TRAF6 is then responsible for the induction
of autophagy following the activation of the TLR4 in macrophages through the ubiquitination of
Beclin1 with K63-ubiquitin chains in murine macrophages RAW 264.7 [71]. Indeed, ubiquitination of
the lysine residue 117 within the BH3 domain of Beclin1 prevents its interaction with the inhibitor
Bcl-2 [71,72]. In addition, Min and colleagues showed that TRAF6 and USP14 compete for the
interaction with Beclin1 in HEK293T (human embryonic kidney 293T) cells and that USP14 negatively
regulates autophagy in THP-1 monocyte cells [73]. TRAF6 and Beclin1 interact through their coiled-coil
domains in the absence of USP14, whereas the interaction is gradually attenuated when the cells are
co-transfected with increasing quantity of USP14. However, the study does not provide any evidence
for the catalytic role of USP14 and instead suggests that the interaction of Beclin1 with USP14 inhibit
TRAF6-mediated ubiquitination of Beclin1 [73]. Additionally, the DUB A20—a downstream target of
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NF-κB—is responsible for the catalytic removal of K63-linked ubiquitin chains on the lysine 117 of
Beclin1 to limit the induction of autophagy in the murine macrophage cell line RAW 264.7 [71].
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Figure 3. Functional roles of eukaryotic deubiquitinating enzymes in autophagy. (A) DEPTOR interacts
with mTOR and inhibits its kinase activity. Under nutrient-rich conditions, DEPTOR is degraded
continuously, and mT R is active, promoting cell growth. However, under nutrient shortage, DEPTOR
is stabilized by deubiquit ation by OTUB1, interacts with mTOR and inhibits its kinase activity,
allowing f r the induction of autophagy. (B) The deubiquiti ation of ULK1 by USP20 allows for its
stabilization and promotion of autophagy induction. (C) Beclin1 is an essential modulator of the
PI3K-III complex. Beclin1 ubiquitination is crucial to its function. Deubiquitination by A20 inhibits
Beclin1 activity by promoting its interaction with the inhibitor Bcl-2. USP14 negatively regulates
Beclin1 activity. Other DUBs positively regulate autophagy by stabilizing Beclin1 (USP9X, USP10,
USP13, USP19). The deubiq it nat on f RALB by USP33 benefits their interac ion and the nduction of
autophagy. Ubiquitination also mediates the degradation of selected argoes by autophagy. (D) The
deubiquitination of α-synuclein aggregates by USP9X favor their degradation by autophagy, while
UCH-L1 contribute to the accumulation of α-synuclein by downregulating its lysosomal degradation.
The deubiquitination of various protein aggregates by ZRANB1 or USP36 impairs their degradation
by autophagy. Invasion by intra-cellular bacteria tends to induce the accumulation of aggregate-like
structures (ALIS) which are ubiquitinated and contribute t th induction of bacterial clearance by
xenophagy; the DUB-like e zyme Ssel secreted by Salm nella deubiquitinates ALIS, resulting in a
downregulation of autophagy and better survival of the bacteria. (E) Mitophagy selectively degrades
mitochondria. USP8 promotes Parkin-mediated mitophagy by deubiquitinating Parkin and promoting
its recruitment to the mitochondria. USP30, s-USP35, and USP15 counteract Parkin by deubiquitinating
Parkin’s substrates, thus impairing mitophagy. (F) Specific ubiquitinated substrates can also be targeted
for autophagy. Deubiquitination of HIF-1α and Connexin-43 (Cx43) by Cezanne and USP8, respectively,
prevents their lysosomal degradation. (G) Autophagos mes can fuse with the endosomes. This fusion
requires the ESCRT machinery as well as AMSH (AtAMSH1 in A. thaliana). USP20 and USP30 to a
lesser extent favor the direction of the β2-adrenergic receptors to the autophagosome for degradation.
In Drosophila, dUSP8 and dUSP12 positively regulate autophagy by contributing to the biogenesis of
the lysosome. (H) Deubiquitination of H2B by USP44 negatively regulates the transcriptional activation
of autophagy. Legend: Colored arrows show the action of DUBs that support (green) or inhibit
(red) autophagy. Pink proteins are molecular inhibitors of autophagy; green proteins are inducers
of autophagy.
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Interestingly, Beclin1 and the Bcl-2 family member, MCL-1, compete for their interaction with
USP9X, which contributes to their stabilization by protecting them from proteasomal degradation in
HEK293T cells [74]. In the same study, it was observed that MCL-1 levels were increased in malignant
tissues from melanoma patients while Beclin1 was destabilized, suggesting that USP9X promotes
tumor progression. However, USP9X function in tumorigenesis appears to be more complex and
context-dependent as independent studies have shown that USP9X can be either a tumor promoter or
suppressor depending on the origin of the cells [75,76]. The addition of K11-linked ubiquitin chains to
Beclin1 by the E3 ligase NEDD4 triggers its degradation by the proteasome [77]. The enzymes USP13
and USP19 are known to process K11-linked ubiquitin chains resulting in the stabilization of Beclin1
in HEK293T cells (for both USP13 and USP19 roles), as well as in MEF, HeLa and Bcap-37 cells (role
of USP13) [78,79]. Although several lysine residues in Beclin1 may be ubiquitinated with K11-linked
chains, USP19 seems to mainly target ubiquitin moieties bound to the lysine 437 of Beclin1 in HEK293T
cells, suggesting that its function may not be redundant, but instead complementary to USP13 [78].
Finally, the DUB USP33 was found to be a regulator of early steps of starvation-induced autophagy
activation by promoting the interaction between Beclin1 and the RAS-like GTPase RALB. Indeed, the
assembly of the complex RALB-EXO84-Beclin1 is made possible by the deubiquitination of RALB at its
lysine residue 47 in HEK293T and HeLa cells [80]. The identification of USP33 as indirectly regulating
Beclin1 activity through the deubiquitination of one of its partners reinforces the hypothesis that the
modification and activation of autophagy machinery components are context-specific.
3.2. Regulation of Selective Autophagy
3.2.1. Aggrephagy
The formation of protein aggregates is a continuous process in the cell, and their degradation by
autophagy, referred to as aggrephagy, is one of the first types of selective autophagy that has been
described. Aggrephagy involves the autophagy receptors p62/SQSTM1 and NBR1 which are recruited
to ubiquitinated protein aggregates [81–84].
The accumulation of protein aggregates that fail to be degraded in neuronal or glial cells is a
hallmark of various neurodegenerative diseases. Aggregation of α-synuclein is characteristic of the
pathogenesis of Parkinson’s disease in which mono- and poly-ubiquitinated α-synuclein are major
constituents of the Lewy bodies [85,86]. Mono-ubiquitination of α-synuclein seems to be required for its
targeting of proteasomal degradation and thus negatively regulates its autophagic degradation. USP9X
interacts with α-synuclein in vitro and in vivo and contributes to the removal of mono-ubiquitin
moieties and favors its targeting for degradation by autophagy rather than the proteasome [87].
Conversely, UCH-L1—a DUB associated with Parkinson’s disease and whose gene is frequently
mutated in familial forms of the pathology [88]—promotes the accumulation of α-synuclein aggregates
in oligodendrocytes [89,90]. Another independent study also reported that membrane-associated
UCH-L1 contributes to α-synuclein neurotoxicity, possibly by negatively regulating its lysosomal
degradation [91] (Figure 3D). Finally, a recent study demonstrates the prevalence of K63-linked
ubiquitin chain conjugates in Lewy bodies, suggesting that their elimination can be primarily ensured
by the lysosomal route rather than the 26S proteasome. In addition, this study identifies USP8 as one of
the best markers of Lewy bodies in human pigmented neurons in sporadic cases of Parkinson’s disease
and demonstrates the ability of USP8 to hydrolyze K63-linked ubiquitin chains from α-synuclein
in vitro [92]. Moreover, Usp8 gene extinction significantly reduces the total level of α-synuclein both
in a Drosophila model of Parkinson’s disease and in human embryonic kidney (HEK293T) cultured
cells [92]. Thus, the presence of USP8 on endosomal membranes (see below) and in Lewy bodies, as
well as its ability to deubiquitinate α-synuclein, makes it a preferred therapeutic target according to
the assumption that inhibition of USP8 could directly promote the elimination of amyloid fibers by the
endocytic and lysosomal pathways.
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It was recently shown that the selective autophagy receptor p62 binds to protein aggregates
modified not only with K63-linked ubiquitin chains but also with K33-linked ubiquitin chains [93,94].
ZRANB1/TRABID is a K29- and K33-specific DUB [95]. Knockdown of ZRANB1 enhances the
recruitment of p62 to K33-associated protein aggregates, suggesting that ZRANB1 is a negative
regulator of aggrephagy; yet, the physiological function of K33-linked ubiquitin chains and the role of
ZRANB1 are not entirely understood [94].
In Drosophila, the p62 homolog Ref(2)P is also implicated in the clearance of ubiquitinated
protein aggregates [96,97]. However, little is known about the regulation of autophagy-associated
ubiquitination processes in flies. The only DUB known to regulate ubiquitin-dependent autophagy
negatively is dUSP36 [98]. This protein negatively regulates the formation of ubiquitinated nuclear
aggregates, while promoting cell growth. Indeed, deletion of the dUSP36 encoding gene results in the
robust accumulation of ubiquitinated protein aggregates, which include the histone protein H2B, and
in the activation of autophagy, independently of the TOR pathway [98] (Figure 3D).
Protein aggregates clearance requires the action of selective receptors to be adequately targeted
for autophagic degradation [3]. NDP52 is an autophagy receptor mostly described for its role in
addressing ubiquitin-decorated bacteria for degradation by autophagy [99,100]. However, a new role
for NDP52 in the formation of TRAF6 aggregates was unveiled [101]. Indeed, NDP52 mediates the
aggregation and selective autophagic degradation of the TLR adaptor molecule TRIF and the signaling
molecule TRAF6 in response to TLR4 stimulation. Ubiquitination of NDP52, mediated by TRAF6, is
necessary for its activity and is counteracted by A20 [101] (Figure 3D).
With the variety of proteins prone to aggregations, it is not surprising that different DUBs
are involved in the regulation of the formation and degradation of protein aggregates. Protein
aggregation is a hallmark of various pathologies, notably neurodegeneration and infection, and a
better understanding of the regulatory mechanisms associated with each pathology will greatly benefit
the development of appropriate and targeted treatments.
3.2.2. Mitophagy
Mitophagy refers to the clearance of exhausted mitochondria by autophagy. The mitochondrial
kinase Pink1 and the E3-ubiquitin ligase Parkin play a central role in the mitochondrial quality control.
Upon mitochondria damage and loss of membrane potential, Parkin is translocated to the outer
mitochondrial membrane (OMM) and activated by stabilized Pink1 [102]. Active Parkin ubiquitinates
a myriad of substrates on the OMM that can be recognized by ubiquitin-binding selective autophagy
receptors [103,104]. So far, three DUBs—USP30, s-USP35, and USP15—have been reported to counteract
Parkin activity following acute mitochondrial depolarization, thus acting as a negative regulator of
mitophagy. USP8 is the only DUB identified so far as a positive regulator of mitophagy (Figure 3E).
USP30 is a mitochondrial enzyme, tethered to the outer membrane of the mitochondria with
its catalytic domain facing the cytoplasm [105]. Several independent studies point out that USP30 is
one of the major DUB regulating mitophagy. Overexpression of USP30 reverses the ubiquitination of
Parkin substrates, such as TOM20, and impairs mitophagy [106–109]. USP30 function in autophagy
is dependent on its catalytic activity as a catalytically inactive mutant USP30-C77A is ineffective
at inhibiting mitophagy [106]. The depletion of USP30 was shown to enhance the degradation of
mitochondria in neuronal and HeLa cell cultures [106,109]. USP30 knockdown also increases the
ubiquitination level on multiple Parkin substrates, thus confirming that USP30 antagonizes Parkin
function. USP30 proteolytic activity is more efficient on K6-linked ubiquitin chains, even though
it can also process K11, K48 and K63 chains [108,110]. The ubiquitin chains targeted by USP30 are
similar to the ones Parkin adds to its substrates, suggesting that these two enzymes act as antagonists
on shared substrates. The majority of the work carried out on the regulation of mitophagy have
relied on cells overexpressing Parkin along with the use of mitochondrial-depolarizing agents. Such
experiments simulate an extreme scenario of mitochondrial stress and interpretations may not be
relevant to basal conditions of mitochondrial clearance [111]. However, recently published work by
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Marcassa and colleagues describes the investigation into the role of USP30 in more physiological
conditions [112]. The authors propose a new model in which USP30 acts upstream Pink1 as the
depletion of Pink1 in cells lacking USP30 abrogated the increased mitophagy induced by USP30
knockdown in U2OS cells [112]. In the same study, USP30 is revealed to regulate the degradation of
peroxisome by autophagy (pexophagy) in a similar way to its role in mitophagy. Like mitochondria,
peroxisomes are the main source of reactive oxygen species (ROS) that can be damaging to the cells if
produced in high quantities [113]. Moreover, contact sites between mitochondria and peroxisomes exist,
and mitochondria were shown to play a role in the generation of peroxisomes [114]; thus reinforcing
the hypothesis of an intrinsic relationship between both organelles. The depletion of USP30 increases
both pexophagy and mitophagy. However, the localization of USP30 on mitochondria and peroxisomes
relies on distinct sequences, suggesting that the role of USP30 in pexophagy is independent to its
mitochondrial function [112]. It is possible that USP30 acts at different levels during the mitophagy or
pexophagy processes depending on the conditions. In basal condition, USP30 could serve as a safety
check-point to avoid mitophagy or pexophagy to be triggered inappropriately.
Besides, other studies identified additional DUBs which may also contribute to the regulation of
mitophagy. USP35 short form (s-USP35) is another DUB that is localized at the mitochondria [109]. In a
similar manner to USP30, overexpression of s-USP35 impairs mitophagy while s-USP35 knockdown
enhances mitochondrial degradation [109].
USP15 is the third DUB identified to antagonize Parkin-mediated mitophagy. Overexpression
of USP15 inhibits mitophagy dependently of its catalytic activity, while depletion of USP15 enhances
mitophagy. Unlike USP30 and s-USP35, USP15 is only rarely localized at the mitochondria [115].
Only one DUB, USP8, may act as a positive regulator of mitophagy through Parkin regulation.
Usp8 knockdown impairs Parkin-mediated mitophagy by preventing Parkin recruitment of depolarized
mitochondria. In this process, USP8 selectively removes K6-linked ubiquitin chains on Parkin and
counteracts Parkin auto-ubiquitination and auto-catalytic activation [116].
Whether and how these DUBs act in concert or within different organs or situations remains to be
determined to fully understand their specific requirements in physiological or stressed conditions.
3.2.3. Targeted Degradation of Cargoes
Proteins can be degraded by autophagy independently of their aggregation in a way that can be
either dependent or independent of their ubiquitination state. To date, only a few substrates, known to
be directly targeted for degradation by autophagy in response to ubiquitination, have been shown to
be regulated by a specific DUB (Figure 3F).
The Hypoxia-Inducible Factor 1, α subunit (HIF-1α) is a transcription factor essential for
cells to adapt rapidly to low oxygen levels (hypoxia). When oxygen is available, HIF-1α is
polyubiquitinated and rapidly degraded either by the proteasome or directly by the lysosome through
chaperone-mediated autophagy [117,118]. The DUB Cezanne/OTUD7B is itself induced by oxygen
deprivation in cultured endothelial cells. Moreover, loss of Cezanne reduces the amount of HIF-1α
protein while Cezanne overexpression stabilizes HIF-1α and protects it from autophagic degradation
in a catalytic-dependent manner by specifically processing K11-linked ubiquitin chains [119]. Mutation
of the CMA-targeting motif (KFERQ motif) of HIF-1α makes it insensitive to Cezanne knockdown, thus
suggesting that Cezanne specifically regulates the degradation of HIF-1α mediated by CMA. Cezanne
is not the only DUB to regulate the ubiquitination status of HIF-1α. Indeed, USP8 is essential for the
removal of ubiquitin moieties on HIF-1α in normoxia, contributing to the maintenance of a basal level
of HIF-1α. In this case, however, USP8 appears to protect HIF-1α from proteasomal degradation [120].
These two studies show that different DUBs can regulate the fate of a shared substrate depending on
the physiology of the cell.
Connexin-43/Cx43 is a member of the connexin family that forms the gap junction channels
between adjacent cells, enabling direct intercellular exchanges between cells, which is another example
of a substrate for at least two different degradative pathways. Indeed, Cx43 polyubiquitination
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triggers its degradation through either the proteasome or the lysosome via endocytosis and
autophagy [121–124]. USP8 interacts with and deubiquitinates Cx43, removing monoubiquitin
moieties as well as K63- and K48-linked ubiquitin chains. Cx43 ubiquitination and degradation
by autophagy are increased in Usp8 knockdown cells [125]. Even though USP8 regulates autophagic
degradation of Cx43 in basal condition, one cannot exclude that USP8 may also affect Cx43 through
the endolysosomal pathways in different conditions as USP8 is well described for its implication in the
endocytosis of various plasma membrane receptors [126–128].
Thus, there are several cases of proteins being degraded through different processes notably as
a result of the linkage of different kinds of ubiquitin moieties and undergoing tight regulation by
specific DUBs.
3.3. Regulation of the Fusion of Endosome to Autophagosome
Autophagy and endocytosis are two conserved and interconnected degradative pathways among
eukaryotes. Moreover, fusion events between autophagosomes and endocytic compartments have
been observed and investigated [129,130]. Endocytosis and autophagy converge not only at the level
of lysosomes but also at the level of early and late endosomes, forming another type of vesicle called
amphisomes. Several DUBs, known for their role in endocytosis, also impact directly or indirectly the
autophagic flux (Figure 3G).
AMSH is a metalloprotease of the JAMM type involved in the sorting of cell-surface receptors at
endosomes [131–134]. AMSH localizes at the endosomes and promotes the recycling of internalized
receptors [135,136]. Disruption of AMSH in mice results in the loss of neurons in the hippocampus and
severe atrophy of the cerebral cortex [137]. An independent study observed that the loss of AMSH in
neurons results in the accumulation of ubiquitinated protein aggregates associated with the autophagy
receptor p62, indicating that the autophagy flux is impaired [138] (Figure 3D). However, at this stage
of the study, it is not possible to discriminate whether the blockade of the autophagy flux results
from an impairment in the endocytic process or a lack of targeting of cargoes to autophagosome,
independently of endocytosis. In the plant model Arabidopsis thaliana, the ortholog AMSH1 interacts
with the ESCRT-III protein VPS2.1 and contributes to autophagic degradation [139] (Figure 3G).
USP8 is a second DUB playing a major role in endocytosis by regulating both the ubiquitination
status of cargoes and members of the ESCRT machinery regulating membrane deformation and
scission events [126–128,140–142]. USP8 has been extensively studied for its role in the regulation
of the trafficking and lysosomal degradation of receptors, such as EGFR, through the endocytic
process [135,143]. In addition to its role in endocytosis, loss of dUSP8 in Drosophila blocks
the progression of autophagy, resulting in the accumulation of Ref(2)P/p62 and ubiquitinated
proteins [144]. As for dUSP8, dUSP12 depletion affects both the autophagic flux and endocytosis
process. Indeed, silencing dUSP12 encoding gene results in the accumulation of autophagosomes
in Drosophila [144], and USP12 negatively regulates the endocytosis and translocation of the Notch
receptor to the lysosomes in both Drosophila and mammalian cells [145]. Although these studies cannot
exclude a direct role of these DUBs in the regulation of autophagy, they support a close imbrication
of endocytosis and autophagy and suggest interdependence of the two processes. This hypothesis is
reinforced by the fact that disruption of the endocytic process using dominant-negative Rab or by their
knockdown also results in impaired autophagy [146].
The particular case of the β2-adrenergic receptors (β2-ARs) also illustrates a reliable
interconnection between the endocytic and autophagic processes and their tight regulation by
ubiquitination. β2-adrenergic receptors (β2-ARs) availability on the plasma membrane is tightly
regulated by balancing their internalization and recycling rates. Misregulation of β2-ARs trafficking
has been associated in various pathologies, including heart failure and asthma [147]. β2-ARs take an
unconventional route to the lysosomes; indeed, after their endocytic internalization, ubiquitinated
β2-ARs are directed to the autophagosomes rather than the lysosomes [148]. The post-endocytic
sorting of the receptor from the endosomes to the autophagosomes is modulated by the proteases
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USP20 and USP33 [149]. However, solely USP20 was shown to promote the deubiquitination of β2-ARs
and their post-endocytic trafficking to autophagosomes. In this process, phosphorylation of USP20 at
serine residue 333 is required for its activity providing an additional level of regulation [148].
Recently, the protein CHMP2A of the ESCRT-III complex was identified to be crucial for the
closure of the autophagosome [150]. Therefore, endosomes-associated DUBs such as USP8 and AMSH,
or other DUBs that remain to be identified, may also play a direct regulatory role in this process
through the regulation of ESCRT-III components activity, as recently shown for CHMP1B during
endocytosis [140].
3.4. Transcriptional Regulation of Autophagy by USP44
The expression of a number of genes related to autophagy is activated upon starvation in
mammalian cell culture. In this process, histone protein H2B monoubiquitination (H2Bub1) is an
essential modification for the regulation of gene transcription. The level of H2Bub1 is controlled
by the protease USP44 which is upregulated after starvation. Knockdown of Usp44 results in the
maintenance of H2Bub1 upon starvation and abolishes the change in expression of starvation-induced
autophagy-related genes. Moreover, downregulation of USP44 encoding gene blocks the induction
of autophagy in mESCs (mouse embryonic stem cells) (Figure 3H). This study thus unveils a
new role for DUB in the transcriptional regulation of autophagy through the modulation of H2B
monoubiquitination [151].
3.5. Regulation of Autophagy by Bacterial and Viral DUB-Like Enzymes
Ubiquitination of microbial molecular patterns is used by eukaryotic cells to tag invasive
pathogens and target them for autophagic degradation. This reaction leads to the accumulation
of ubiquitinated protein aggregate known as ubiquitinated aggresome-like induced structures (ALIS).
Such aggregates contribute to the upregulation of autophagy and the removal of intracellular pathogens.
In response to this host defense mechanism, intracellular pathogens, such as bacteria or viruses, have
developed strategies to hijack the host ubiquitin pathway by expressing DUB-like enzymes able to
counteract ubiquitination and permit them to escape their elimination by autophagy.
For instance, the intracellular pathogenic bacteria Salmonella enterica serovar Typhimurium
(S. Typhimurium) counteracts the ALIS-induced autophagy by translocating a DUB-like enzyme, SseL
(Salmonella-secreted factor L), into the cytosol. Lysates from mouse macrophages infected with ∆sseL
mutant bacteria are enriched in ubiquitinated proteins, and immunofluorescence experiments revealed
that these bacteria are more prone to ubiquitination and recognition by autophagy markers such as LC3
or p62 [152,153]. Secreted SseL deubiquitinates ALIS and the Salmonella-containing vacuoles, reducing
the induction of autophagy, further promoting the survival and replication of S. Typhimurium [152]
(Figure 3D).
Like Salmonella, Legionella is an intracellular bacterium that can establish niches in cytoplasmic
vacuoles which allows for the survival and replication of the bacteria. The Legionella pneumophila
effector protein RavZ is a secreted cysteine protease that interferes with the autophagy machinery by
irreversibly deconjugating LC3 from the autophagosome membrane [154]. LC3 is an autophagy-related
ubiquitin-like protein anchored to the autophagosome membrane. The process leading to LC3
lipidation and association to the membrane is similar to the ubiquitination process and requires
a ubiquitin-like conjugation system. RavZ deconjugates LC3 from the autophagosome membrane
by hydrolyzing the amide bond between the C-terminal glycine residue and an adjacent aromatic
residue; the lack of terminal glycine residue prevents the conjugation of LC3 to the membrane [154,155].
RavZ can also process conventional ubiquitin chains and prevent the targeting of intracellular bacteria
for autophagic degradation [156]. Indeed, using a co-infection system with Salmonella and Legionella,
Kubori and colleagues showed that Legionella RavZ protease prevents the recruitment of the autophagy
receptors p62 and NDP52 to the Salmonella-containing vacuoles. The lack of autophagy receptors at
the SCVs is due to the removal of ubiquitin moieties from the SCVs by RavZ [156]. It was recently
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shown that RavZ specificity toward LC3 anchored to the autophagosomal membrane depends on its
interaction with PI3P [157]; this observation suggests that RavZ activity as DUB on ubiquitin coats
depends on the lipid structure of the nearby vacuole.
Autophagy also targets viruses; yet, many viruses exploit autophagy for their replication [158].
Coronaviruses induce the formation of double-membrane vesicles that allow for their replication and
are often decorated with LC3 and cell infection with coronaviruses is often accompanied with induction
of autophagy [159]. The non-structural protein PLP2-TM, which is a transmembrane papain-like
protease with deubiquitinating activity [160], is sufficient for the accumulation of autophagosomes
in different cell lines. However, its role in the regulation of autophagy is independent of its protease
activity [161]. PLP2-TM interacts with LC3 and promotes the accumulation of autophagosomes by
blocking their fusion with the lysosomes. In their study, Chen and colleagues suggest that PLP2-TM
blocks autophagosome-lysosome fusion through its interaction with Beclin1, a prime target for viruses
that manipulate the autophagy pathway [162]. PLP2-TM also promotes the interaction of STING
(stimulator of interferon genes) with Beclin1, possibly to impede the activation of downstream antiviral
responses, accentuated by the deubiquitination of components of the signaling cascade such as RIG-1
or TRAF3 [161,163].
These studies provide fascinating examples of possible coevolution and adaptation of the
pathogens with their host, where pathogens managed to bypass the host’s defense to their own benefit.
4. Targeting Deubiquitinating Enzymes Acting in Autophagy for Therapeutic Purpose
Ubiquitination regulates major cellular functions by controlling protein stability and activity,
and defects in this process contribute to the development of many diseases. In some cases,
ubiquitin-dependent autophagic processes constitute entry points to design new treatments.
Depending on the context, however, autophagy can either be beneficial and contribute to survival and
recovery or have adverse effects. As such, there is a need for in-depth understanding of autophagy
function and regulation in pathological or physiological situations to define in which situation the
inhibition of a particular DUB will be beneficial or detrimental. Interestingly, the design of chemical
tools is also a powerful strategy to probe the effect of DUBs inhibition to help both the understanding
of their role in the regulation of autophagy and the design of future treatments to modulate autophagy
in the corresponding pathologies.
4.1. The Challenge of Developing Drugs Targeting DUBs
Efficiency and usability of an inhibitor depends on its specificity. As such, the discovery of
DUB-focused drugs has been challenging [20]. Indeed, although DUBs have a catalytic pocket that
is suitable for drug development, their sequence and structure are very similar. Moreover, DUBs are
flexible enzymes, and the regulation of their activity can involve allosteric effects as described for
several DUBs that alternate between active and inactive conformations [164–169]. For instance, the
free catalytic domain of USP7 undergoes significant structural modifications when it is complexed
to Ubal (ubiquitin aldehyde, an irreversible DUB inhibitor) [164,170]. Recent publications of the
dynamic interaction of USP7 with specific small-molecule inhibitors demonstrated that the binding
of the molecules into the active site of USP7 modifies the catalytic residue C223. This modification
of the active site of USP7 results in its inability to change conformation and perform the cleavage of
ubiquitin chains. These studies show that the development of specific inhibitors binding to the active
site of DUBs is a realistic approach, opening new avenues in the field [171,172]. In addition to intrinsic
modulation of their activity and substrate specificity, some DUBs require cofactors. For instance, the
full activation of USP19 requires its interaction with Hsp90, which promotes the binding of ubiquitin
to the catalytic domain of USP19 [173]. Another example is the proteasome-associated enzyme USP14,
whose activity is strongly enhanced when in association with the proteasome [66].
Despite the complexity of the regulation of DUBs activity, much effort has been placed in the
identification and development of small-molecule regulating DUBs catalytic activity. Some of the most
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successful small-molecules affecting autophagy the process, through the inhibition of the activity of
autophagy-associated DUBs, are shortly introduced hereafter.
4.2. Characterised Inhibitors of DUBs Acting in Autophagy
Screens for inhibitors of DUBs sought to identify new small-molecules with potential in two
main therapeutic fields, for cancer treatment and neurodegeneration (reviewed in [20]). In both fields,
some of the inhibitors’ targets play a role in the regulation of autophagy that possibly contributes
to pathogenesis.
USP14 is an enzyme associated with the proteasome, which plays an essential role in the regulation
of protein turnover. The role of USP14 is particularly important in neurons to maintain synaptic
functions and constitutes an appealing target for drug development in order to modulate the activity
of the proteasome [174]. A screen of 63,052 compounds using proteasome reconstituted with USP14,
led to the identification of the first inhibitor of USP14. The small-molecule IU1 inhibits specifically
USP14 with an IC50 of 4–5 µM [66]. The inhibitor IU1 blocks the activity of USP14 only in the
presence of the proteasome, suggesting that it binds only to the activated enzyme. Moreover, the
compound IU1 abrogates the catalytic activity of USP14 without affecting its noncatalytic regulatory
function [66]. However, with the growing number of USP14 substrates identified, there was a need for
the development of IU1 analogs with improved selectivity over the USP14-substrate complexes. A
curated screen of 87 variants of IU1 led to the identification of IU1-47 as a new potent inhibitor of USP14.
IU1-47 treatment of murine primary neuron cultures and in neurons derived from human-induced
pluripotent stem cells (iPSC) accelerates the degradation of the microtubule-associated protein Tau,
which is implicated in many neurodegenerative diseases. Besides, the inhibition of USP14 by IU1-47
induced an increase of the autophagy flux, consistent with the increased degradation rate of Tau [175].
As mentioned above, UCH-L1 is a negative regulator of autophagy widely studied for its
implication in Parkinson’s disease and its contribution to the aggregation of α-synuclein as a result
of autophagy blockade [86,89]. UCH-L1 is also expressed in various primary lung tumors while
not detectable in normal, healthy lung tissue, suggesting a possible contribution to cancer [176].
Because of the correlation between UCH-L1 and tumor progression, as well as its implication
in neurodegenerative disease, UCH-L1 is a recognized target for the development of therapeutic
inhibitors. As such, the compound LDN-57444 was identified in a high throughput drug screening as
a specific UCH-L1 inhibitor. Treating H1299 lung cancer cell line with this compound significantly
reduces the cell proliferation rate [177]. NSC632839 is another inhibitor that affects UCH-L1 activity.
However, NSC632839 activity is not specific to UCH-L1, and it is already known to inhibit USP2
and USP7 [178,179]. The amount of p62 in cells is reduced after treatment with both LDN-57444 and
NCS632839, suggesting that these drugs could prevent the accumulation of protein aggregates [178].
Therefore, these inhibitors may constitute new tools to investigate further the implication of UCH-L1
in Parkinson’s disease and evaluate whether UCH-L1 inhibition favors the clearance of α-synuclein
aggregates in neurons.
Inhibition of early regulators is another strategy to inhibit autophagy in some situations.
The inhibitor WP1130, which targets USP9X, was reported to lead to an increase in ULK1 ubiquitination,
inducing its transfer to the aggresomes and its inhibition, further resulting in the blockade of autophagy
in several cultured cell lines, including the bone osteosarcoma U2OS cell line [180]. It was speculated
that the inhibition of USP9X could be responsible for the accumulation and subsequent aggregation of
ubiquitinated ULK1. However, silencing Usp9X did not result in changes in ULK1 expression level
when cells were treated with WP1130. This could be because WP1130 is only partially specific and
could have other targets in vivo that remain to be discovered [180,181].
In order to screen and select new small-molecules interfering with autophagy in mammalian cells,
an imaging-based assay has been optimized by Liu and colleagues that makes use of cells expressing
the autophagy marker GFP-LC3 to quantify the accumulation of autophagosomes [79]. Using this
assay, they screened the ICCB known bioactives library, a collection of 472 compounds, and they
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identified the inhibitor spautin-1 (specific and potent autophagy inhibitor 1). Spautin-1 inhibits the
catalytic activity of both USP10 and USP13 with an IC50 of ~0.6–0.7 µM. These two DUBs are involved
in the regulation of Beclin1 ubiquitination in the Vps34 complex and, therefore, constitute an entry
point to modulate the initiation of autophagy. Cancer cell lines treated with spautin-1 demonstrated
an increased cell death rate under starvation conditions. As such, spautin-1 constitutes a potential lead
for the development of autophagy inhibitors for anti-cancer therapies [79].
Because of its essential function in mitophagy, which is crucial to clear damaged mitochondria
notably in neuronal cells, several small-molecule inhibitors of USP30 have been developed in
the past few years. For example, based on a phenotypic screening, it was shown that the
inhibition of USP30 by the compound 15-oxospiramilactone enhances the activity of USP30’s
targets Mfn1 and Mfn2—two GTPases anchored at the OMM and essential for tethering adjacent
mitochondria—and promotes mitochondrial fusion, thus contributing to the restoration of the
mitochondria network [182]. More recently, an in vitro study identified a new small-molecule
MF-094, as a potent and selective inhibitor of USP30. This compound has the opposite effect of
15-oxospiramilactone, as MF-094-mediated inhibition of USP30 accelerates mitophagy [183]. These two
studies highlight the fact that the same DUBs can be involved in different processes, dependent on the
signal they may receive and the interaction within different protein complexes.
There is no doubt that new inhibitors of DUBs will arise with problems related to the existence
of several substrates or to poor selectivity, requiring in-depth analysis of the selected compounds in
different cell types and stress situations before any preclinical assays. Interestingly, these investigations
may tell a lot about how DUBs regulate autophagy and other cell processes, and may be used as
molecular tools to unveil regulatory mechanisms.
5. Conclusions
Protein ubiquitination is an essential, reversible, posttranslational modification involved
in virtually every cellular process. The past decades have seen remarkable progress in the
understanding of the function of DUBs, their mechanism of action and regulation. Recently, there
has been an increasing body of evidence that ubiquitination plays a crucial role in regulating
autophagy, and DUBs intervene at multiple steps in autophagy. Deregulation in both autophagy
and ubiquitination/deubiquitination processes have been linked to many pathologies such as
neurodegenerative diseases, cancer onset and progression, and different kinds of viral or bacterial
infections. Also, considerable effort was placed on the development and optimization of small-molecules
acting as DUBs inhibitors. Such molecules can serve not only as leads for the development of drug-like
molecules but also as tremendous useful tools to investigate the molecular mechanism of autophagy
and its regulation by the ubiquitin system. By the development of molecules targeting protein-protein
interaction instead of the catalytic activity, it could be possible to manipulate and orientate precisely
the function of a DUB towards a given process and/or target to avoid pleiotropic effects.
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